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In recent years, there has been a great increase in seizures and forensic analysis of new psychotropic substances (NPS) in the state 
of Rio Grande do Sul, Brazil. The analysis of these compounds needs to be performed in biological samples in cases of violent 
deaths. A sensitive and reliable liquid chromatography-tandem mass spectrometry with electrospray ionization interface (LC-ESI-
MS/MS) method was developed and validated for qualitative analysis of 51 NPS in whole blood forensic samples. Synthetic 
cathinones, phenethylamines, opioids, tryptamines, synthetic cannabinoids, and other hallucinogens and stimulants were included 
in the method. The validation parameters assessed were specificity, limit of detection, retention time precision, and matrix effect. 
Drug free pools (n=6) were used for validation, including post mortem samples as well as from living individuals. Adulterants, 
pharmaceuticals, metabolites, and other illicit drugs, totalling 39 compounds, were analyzed and no interference was noticed. The 
detection limits obtained were suitable for evaluation at recreational and non-fatal levels of consumption, mostly. The results 
revealed an appropriate matrix effect in 24 out of 51 substances tested, indicating the potential for future quantitative analysis with 
this method for these drugs. The developed and validated method is easy to implement, fast, with low cost, and suitable for use in 
routine forensic toxicology laboratory analysis. 
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Abbreviations 
 
25B-NBOH  2-([2-(4-bromo-2,5-dimetoxiphenyl)etylamino]metyl)phenol 
25B-NBOMe  2-(4-bromo-2,5-dimethoxyphenyl)-n,n-bis(2-methoxybenzyl)ethanamine 
25C-NBOH  2-(((4-chloro-2,5-dimethoxyphenethyl)amino)methyl)phenol 
25C-NBOMe  2-(4-chloro-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethanamine 
25E-NBOH  2-[[2-(4-ethyl-2,5-dimethoxy-phenyl)ethylamino]methyl]phenol 
25I-NBOH  2-({[2-(4-iodine-2,5-dimethoxy-phenyl)ethyl]amino}methyl)phenol  
25I-NBOMe  2-(4-iodine-2,5-dimethoxyphenyl)-n-(2-methoxybenzyl)ethanamine 
2C-B   4-bromo-2,5-dimethoxyphenetylamphetamine  
2C-E   4-ethyl-2,5-dimethoxyphenetylamine  
5-MeO-MIPT  5-methoxy-n-isopropyl-n-methyltryptamine 
ADB-Fubinaca n-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide 
Alpha-PVP  α-pyrrolidinopentiophenone 
bk-DMBDB  dibutylone 
bk-MDEA  ethylone 
bk-MDMA  methylone 
CP47-497  rel-2[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol 
CP47-497-C8  rel-2-[(1S,3R)-3-hydroxycyclohexyl]-5- (2-methylnonan-2-yl)phenol 
DMAA   1,3-dimethylpentylamine 
DMT   n,n-dimethyltryptamine 
DOB   4-bromo-2,5-dimethoxyamphetamine 
DOC   4-chloro-2,5-dimethoxyamphetamine 
DOI   4-iodine-2,5-dimethoxyamphetamine 
HU-210 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol 
JWH-018  (1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone 
JWH-073  (1-butyl-1H-indol-3-yl)(naphthalen-1-yl)methanone 
JWH-1503  [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone 
JWH-200  [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-methanone 
JWH-250  1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)-ethanone 
LSD   lysergic acid diethylamide 
MBDB   n-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine 
mCPP   1-(3-chlorophenyl)piperazine 
MDA   3,4-methylenedioxyamphetamine  
MDEA   3,4-methylenedioxy-n-ethylamphetamine 
MDMA   3,4-methylenedioxymethamphetamine 
PCP   phencyclidine 
TFMPP   1-(3-trifluoromethylphenyl)piperazine   
THC   tetrahydrocannabinol 
TH-PVP   2-pyrrolidin-1-yl-1-tetralin-6-yl-pentan-1-one 
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Introduction 
 
The use of psychoactive substances is a worldwide 
phenomenon with incalculable consequences on society. The 
World Drug Report 2019, by the United Nations Office on 
Drugs and Crime (UNODC), reported that 35 million people 
around the world suffer from drug use disorders, revealing 
that the adverse health consequences of drug use are more 
severe and widespread than previously thought (1). 
Older drugs, such as cocaine and Cannabis sativa, remain 
dominant, but the drug market is now peppered with a vast 
array of synthetic psychoactive substances. Clandestine 
laboratories manufacture synthetic drugs in different 
countries all the time showing the need for broader 
international cooperation to promote balanced and integrated 
criminal health and justice responses to supply and demand. 
New psychoactive substances (NPS), which induce stimulant 
and hallucinogenic effects even in small amounts, are 
designed to mimic established substances with similar 
properties that are under international control, such as 
amphetamine, methamphetamine, dimethoxyamphetamines, 
piperazines, cathinones, and several other drugs. These drugs 
are sold on the internet and they appear specially on the dance 
scene in the form of various tablets or blotters paper with 
questionable composition and potential risk for intoxications 
and death (1). 
The number of stimulant NPS identified over the period 
2009–2017 increased more than fourfold, from 48 substances 
in 2009 to a peak of 206 in 2015, a number that has remained 
stable since then. In most years, stimulant NPS have been the 
largest group of NPS identified and reported by Member 
States, followed by synthetic cannabinoids. Over a third of all 
NPS identified since 2009 are stimulants, including 39 per 
cent of all NPS identified in 2017. Most of the new stimulant 
NPS identified on the markets and reported to UNODC in 
2017 were cathinones or phenethylamines (1). 
Although the mortality associated with NPS is still not 
comparable to that of opiate-related deaths, for example, 
there is uncertainty about the number of undetected cases, and 
this issue is becoming a more significant challenge for post 
mortem forensic toxicology. The measurement of NPS in 
biological forensic samples has become an extended topic 
over the present decade for monitoring trends of use and 
deaths among young people. According to the post mortem 
toxicology Technical Report in Europe, there is an urgent 
need to increase the screening capacity of many toxicology 
laboratories to determine certain NPS groups in biological 
samples, especially new multi-target methods (2). 
Although stimulants amphetamine derivatives are analyzed 
by gas chromatography (GC), generally equipped with 
nitrogen–phosphorus or mass detectors, liquid 
chromatography (LC) has some advantages in comparison to 
GC. LC does not promote thermal degradation of the analyte 
and it does not require samples to be volatilized. To improve 
GC properties, some additional steps such as selective 
derivatization, are mandatory. While giving excellent results, 
the use of some derivatizing agents in GC increase cost and 
time of analysis and can be pernicious for column lifetime 
due to decomposition of the stationary phase making the 
application of LC analysis advantageous (3). The 
hyphenation of LC to high resolution mass spectrometry 
based on triple quadrupole for target analysis has advantages 
for identification of NPS in low levels in biological samples 
due to its increased resolving power and sensibility. 
The simultaneous determination of a broad number of 
compounds in one injection, with a corresponding reduction 
of time and costs, without additional materials needed for 
sample preparation, is very important in the forensic routines 
of underdeveloped countries. The aim of the presented work 
was to establish a broad analytical tool for the analysis of 
different types of NPS in human whole blood post mortem 
samples, by liquid chromatography-tandem mass 
spectrometry with electrospray ionization interface (LC-ESI-
MS/MS) method, according to the reality of the drugs seized 
in recent years in the state of Rio Grande do Sul (RS), Brazil 
(4-6). The study project was approved by the Research Ethics 
Committee of the Federal University of Rio Grande do Sul 
prior to the initiation of the study, under number 2.532.550. 
 
Experimental 
 
Materials, chemicals, and reagents 
 
Certified reference standards for 25B-NBOMe (90.2%), 25C-
NBOMe (89.6%), 25I-NBOMe (90.5%), 2C-B (87.0%), bk-
MDMA (84.7%), heroine (90.0%), JWH-1503 (0.1 mg mL-
1), LSD (0.025 mg mL-1), MBDB (84.1%), and mephedrone 
(82.6%) compounds were purchased from Lipomed, Inc. 
(Cambridge, MA, USA); for DOB (1.0 mg mL-1), DOI (1.0 
mg mL-1), DMAA (1.0 mg mL-1), Nordiazepam-d5 (1.0 mg 
mL-1, standard internal), and TFMPP (1.0 mg mL-1) were 
purchased from Cerilliant Corporation (Round Rock, TX, 
USA); for mCPP (99.7%) was purchased from LGC GmbH 
(Luckenwalde, BR, Germany); for diethylpropion (98.8%) 
and fenproporex (98.7%) were obtained from Aché 
Pharmaceutical Laboratories (Guarulhos, SP, Brazil); for 
CP47-497 (100.0 µg mL-1), CP47-497-C8 (100.1 µg mL-1), 
HU-210 (100.0 µg mL-1), JWH-200 (100.0 µg mL-1), JWH-
250 (100.0 µg mL-1), JWH-018 (100.0 µg mL-1), JWH-073 
(100.0 µg mL-1), MDA (100.1 µg mL-1), MDEA (99.9 µg mL-
1), MDMA (99.9 µg mL-1), methamphetamine (100.3 µg mL-
1), methylphenidate (100.3 µg mL-1), PCP (100.2 µg mL-1), 
phentermine (100.0 µg mL-1), cannabinol (100.4 µg mL-1), 
fentanyl (50.0 µg mL-1), and alfentanyl (50.0 µg mL-1) were 
purchased from Agilent Technologies (Santa Clara, CA, 
USA); and for bupropion (100.7%) and sibutramine (100.0%) 
were obtained from Spengler Compounding Pharmacy (Porto 
Alegre, RS, Brazil). 
Reference standard including 25B-NBOH, 25C-NBOH, 25E-
NBOH, 25I-NBOH, 2C-E, 5-MeO-MIPT, ADB-Fubinaca, 
alpha-PVP, clobenzorex, bk-DMBDB, DOC, bk-MDEA, 
DMT, N-ethylpentylone, and TH-PVP were obtained from 
materials seized by Civil Police of RS, Brazil and were 
identified by, at least, five different analytical technics 
including A category according SWGDRUG guidelines (7), 
in cooperation studies among the Laboratory of Criminal 
Investigation (DPL-IGP/RS), Federal Laboratory of 
Agricultural Defense (Lanagro-RS), Federal University of 
Health Sciences of Porto Alegre (UFCSPA), and Federal 
University of RS (UFRGS) all located in Porto Alegre, RS, 
Brazil. 
Methanol (HPLC grade) was purchased from J.T. Baker 
(Center Valley, MA, USA), sodium hydroxide (ACS grade) 
was purchased from Neon (Suzano, SP, Brazil), sodium 
nitrite (ACS grade) was purchased from Ecibra (Santo 
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Amaro, SP, Brazil), dichloromethane (HPLC grade) was 
purchased from Honeywell (Charlotte, NC, USA), and butyl 
chloride (HPLC grade) was purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Ultrapure water was obtained by 
purification of distilled water in-house using Purelab (Elga, 
UK). Formic acid and ammonium formate were purchased 
from Agilent Technologies (Santa Clara, CA, USA). 
All related substances used in specificity tests (Table 1), as 
well as all consumables, were provided by the Toxicology 
Division of DPL-IGP/RS, through authorization number 
083/2017 present in the process number 17/1205-0001343-1. 
 
Table 1 Substances analyzed by LC-ESI-MS/MS in whole blood at therapeutic or recreational concentrations [11,12], to evaluate the specificity 
of the developed method. 
Substance Description Concentrations evaluated (ng mL-1) 
11-hydroxy-THC THC metabolite 1 and 100 
11-nor-9-carboxy-THC THC metabolite 1 
Acetaminophen analgesic 2,500 and 9,000 
Alprazolam anxiolytic 5 
Amitriptyline antidepressant 14 and 50 
Amphetamine stimulant 14 and 20 
Atropine muscarinic antagonist used in hospital care 2 and 14 
Benzoylecgonine cocaine metabolite 14 and 50 
Bromazepam anxiolytic 50 and 80 
Caffeine stimulant and cocaine adulterant 14, 2,000 and 2,500 
Carbamazepine anticonvulsant 2,000 
Carisoprodol muscle relaxant 14 and 1,500 
Chlorpheniramine antihistamine 1 and 3 
Citalopram antidepressant 14, 20 and 50 
Cocaethylene cocaine metabolite in the presence of ethanol 10 and 14 
Cocaine Erythroxylum coca active stimulant 14 and 50 
Cotinine present in tobacco and nicotine metabolite 14 and 30 
Dextromethorphan antitussive 10 and 14 
Diazepam anxiolytic 14, 20 and 100 
Dipyrone analgesic 10,000 
Fluoxetine antidepressant 100 and 120 
Ibuprofen analgesic 15,000 
Ketamine anesthetic 100 and 1,000 
Lamotrigine anticonvulsant and mood stabilizer 1,000 
Levamisole anthelmintic and cocaine adulterant 100 
Lidocaine anesthetic and cocaine adulterant 14 and 1,000 
Mazindol anorectic 2 
Mirtazapine antidepressant 30 
Nicotine present in tobacco 1 and 14 
Olanzapine antipsychotic 20 
Omeprazole antacid 50 
Ritalinic acid methylphenidate metabolite 5 and 20 
Sertraline antidepressant 10, 14 and 50 
Sildenafil erectile dysfunction 50 
Tadalafil erectile dysfunction 90 
Tetrahydrocannabinol Cannabis sativa active substance 1 and 100 
Theobromine present in chocolate 1,000 
Venlafaxine antidepressant 100 
Zolpidem hypnotic 80 
Instrumentation 
 
Nitrogen was generated using a Genius 1050 nitrogen 
generator by Peak Scientific (Billerica, MA, USA). An 
Agilent Technologies 6420 Triple Quad (Santa Clara, CA, 
USA) equipped with auto sampler thermostatically controlled 
(4°C) was used to analyze samples. Separation was achieved 
using an Agilent Technologies Series 1260 Infinity II LC 
system equipped with Agilent C18 Zorbax Eclipse Plus (2.1 x 
100 mm; 1.8 µm particle size) column and an Agilent Eclipse 
XDB-C8 guard column (4.6 x 12.5 mm, 5 µm particle size) 
in a thermostatically controlled column compartment (50oC).  
The mobile phase consisted of 0.1% formic acid and 5 mM 
ammonium formate in ultrapure water (A) and 0.1% formic 
acid and 5 mM ammonium formate in methanol (B). A flow 
rate of 0.4 mL/min was maintained using the gradient elution 
profile as follows: 95% A and 5% B; 50% A and 50% B (2.8 
min); 100% B (13.6-18.8); 95% A and 5% B (18.9 min). The 
total acquisition time was 18.9 min with post time 6 min for 
re-equilibration. The LC triple quadrupole was equipped with 
an electrospray ionization interface source (ESI), under the 
following conditions: drying gas was N2 12 L min-1, drying 
gas temperature 320oC, nebulizer 30 psi, and capillary 
voltage 3500 V (positive mode) and 3000 V (negative mode). 
Analytical conditions for each substance are given in Table 2. 
Acquisition and qualitative analysis were performed under 
dynamic multiple reaction monitoring mode (dMRM) in 
Agilent MassHunter® software. 
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Table 2 Substances analyzed by LC-ESI-MS/MS in whole blood, with their retention times, monitored transitions, analytical conditions, and 
detection limits obtained. 
Substance RTa (min) Precursor (m/z) Fragments (m/z) FEb (V) CEc (V) Polarity LD (ng mL-1) 
25B-NBOH 7.5 366.0 105.0, 91.0 and 77.0 120 75, 55 and 40 positive * 
25B-NBOMe 8.1 380.1 121.1 and 91.1 120 18 and 58 positive 0.8 
25C-NBOH 7.3 322.1 199.0 and 107.0 120 25 and 35 positive * 
25C-NBOMe 7.8 336.1 121.1 and 91.1 120 18 and 50 positive 0.7 
25E-NBOH 8.6 316.2 193.0, 178.0 and 107.0 120 25, 30 and 40 positive * 
25I-NBOH 7.9 414.1 291.1 and 107.1 120 22 and 38 positive * 
25I-NBOMe 8.5 428.1 121.1 and 91.1 93 20 and 48 positive 0.5 
2C-B 5.9 260.0 243.1 and 228.1 100 10 and 18 positive 15 
2C-E 6.7 210.1 193.2 and 178.2 80 10 and 18 positive * 
5-MeO-MIPT 5.0 247.2 174.1 and 86.1 65 16 and 10 positive * 
ADB-Fubinaca 11.5 383.2 253.3 and 109.0 133 33 and 57 positive * 
Alfentanyl 6.9 417.3 268.1, 197.0 and 165.0 128 16, 24 and 36 positive 0.7 
Alpha-PVP 5.6 232.2 91.1 and 77.1 130 26 and 54 positive * 
bk-DMBDB 4.9 236.1 191.1, 161.1 and 65.0 75 10, 16 and 48 positive * 
bk-MDEA 4.6 222.1 204.2, 174.2 and 91.1 100 10, 18 and 46 positive * 
bk-MDMA 4.3 208.1 190.2 and 160.2 100 10 and 14 positive 35 
Bupropion 6.1 240.1 184.1, 166.0 and 131.1 150 10, 20 and 40 positive 425d 
Cannabinol 15.0 311.2 293.2 and 223.0 126 16 and 20 positive 35 
Clobenzorex 7.1 260.1 125.0 and 91.1 150 20 and 20 positive * 
CP47-497 15.0 317.2 299.2 and 245.2 232 24 and 32 negative 120d 
CP47-497-C8 15.5 331.3 313.2, 259.2 and 159.0 247 24, 32 and 60 negative 150d 
Diethylpropion 4.7 206.2 105.1 and 77.2 80 20 and 48 positive 20 
DMAA 5.1 116.1 57.1 and 41.0 55 10 and 24 positive 360 
DMT 4.4 189.1 144.1 and 58.1 55 12 and 8 positive * 
DOB 6.2 274.0 229.0, 178.1 and 105.1 60 16, 20 and 44 positive 15 
DOC 6.0 230.1 213.1 and 185.0 150 10 and 20 positive * 
DOI 6.7 322.0 305.0 and 105.0 36 17 and 57 positive 15 
Fenproporex 4.5 189.1 119.1 and 91.1 150 5 and 10 positive 30d 
Fentanyl 6.5 337.2 216.1, 132.0 and 103.0 146 20, 32 and 60 positive 0.8 
Heroin 5.4 370.2 211.1 and 58.1 150 40 and 40 positive 15d 
HU-210 15.4 387.3 71.1 and 43.1 103 28 and 52 positive 50d 
JWH-018 14.3 342.2 155.0 and 127.1 95 24 and 56 positive 20d 
JWH-073 13.6 328.2 200.1, 155.0 and 127.1 133 24, 24 and 52 positive 10d 
JWH-1503 12.8 360.2 155.0 and 127.1 138 24 and 48 positive 0.8 
JWH-200 9.2 385.2 155.0 and 114.1 113 20 and 32 positive 10d 
JWH-250 13.6 336.2 121.1 and 91.1 98 16 and 48 positive 10d 
LSD 6.0 324.2 223.1 and 207.1 150 20 and 40 positive 5 
MBDB 5.3 208.1 177.1 and 147.1 150 10 and 10 positive 15 
mCPP 5.5 197.1 154.0 and 118.1 103 20 and 36 positive 25 
MDA 4.6 180.1 163.1 and 105.1 80 4 and 24 positive 2 
MDEA 5.0 208.1 163.1 and 133.1 98 8 and 16 positive 2 
MDMA 4.7 194.1 163.1 and 105.1 80 8 and 24 positive 0.3 
Mephedrone 5.1 178.1 160.2 and 145.2 100 10 and 22 positive 80d 
Methamphetamine 4.6 150.1 119.1 and 91.1 75 8 and 20 positive 2 
Methylphenidate 5.6 234.1 84.1 and 56.1 123 20 and 56 positive 1 
N-ethylpentylone 5.7 250.1 232.3 and 202.2 120 10 and 18 positive * 
Nordiazepam-d5 (IS) 9.5 276.1 213.1 and 140.0 150 40 and 40 positive not applicable 
PCP 6.3 244.2 91.1 and 86.2 75 36 and 8 positive 0.3 
Phentermine 5.1 150.1 133.0 and 105.0 75 8 and 16 positive 30 
Sibutramine 8.9 280.2 139.0 and 125.0 150 10 and 20 positive 45d 
TFMPP 6.1 231.1 188.1 and 44.0 123 20 and 20 positive 15d 
TH-PVP 8.6 286.2 215.2 and 145.2 150 18 and 30 positive * 
aRT retention time; bFE fragmentor energy; cCE collision energy; dabove the recreational or therapeutic concentration [11,12]; 
*reference chemical of no known purity. 
 
Preparation of standards and reagents 
 
Solutions containing structurally related substances or 
substances that could be present in the forensic biological 
samples, such as some metabolites, antidepressants, 
anxiolytics, illicit drugs, adulterants, and other 
pharmaceuticals were prepared in methanol and evaluated in 
the specificity test in recreational or therapeutic 
concentrations (Table 1). 
Working standards solutions of each of the 51 compounds 
target (Figure 1) were prepared in methanol for the 
fortification of negative blood samples. The isotopically 
labelled internal standard solution was diluted in methanol at 
1.0 µg mL-1. Sodium hydroxide solution was prepared in 
ultrapure water at 0.2 M. Sodium nitrite solution was 
prepared in ultrapure water at 5 mg L-1. The elution solvent 
was prepared daily. The extraction mixture solvent consisted 
of dichloromethane/butyl chloride 1:4 (v/v) and the 
resuspension solvent consisted of the mobile phase mixture A 
and B (1:1).
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Structure Substance R1 R2 R3 R4 R5 R6 R7 
A 
2C-B Br H H CH3O CH3O H H 
2C-E CH3CH2 H H CH3O CH3O H H 
DOB Br CH3 H CH3O CH3O H H 
DOC Cl CH3 H CH3O CH3O H H 
DOI I CH3 H CH3O CH3O H H 
Bupropion H CH3 O H Cl H (CH3)3C 
Clobenzorex H CH3 H H H H C6H4ClCH2 
Diethylpropion H CH3 O H H CH3CH2 CH3CH2 
Fenproporex H CH3 H H H H CNCH2CH2 
Mephedrone CH3 CH3 O H H H CH3 
Methamphetamine H CH3 H H H H CH3 
Phentermine H (CH3)2 H H H H H 
Sibutramine Cl (CH3)2CHCH2 (CH2)3 H H CH3 CH3 
B 
25B-NBOH Br OH      
25B-NBOMe Br CH3O      
25C-NBOH Cl OH      
25C-NBOMe Cl CH3O      
25E-NBOH CH3CH2 OH      
25I-NBOH I OH      
25I-NBOMe I CH3O      
C 
bk-DMBDB O CH3CH2 CH3 CH3    
bk-MDEA O CH3 H CH3CH2    
bk-MDMA O CH3 H CH3    
MBDB H CH3CH2 H H    
MDA H CH3 H H    
MDEA H CH3 H CH3CH2    
MDMA H CH3 H CH3    
N-ethylpentylone O CH3CH2CH2 H CH3CH2    
D 
5-MeO-MIPT CH3O (CH3)2CH      
DMT H CH3      
E 
Alfentanyl CH3CH2N4CO CH3OCH2      
Fentanyl C6H5 H      
F 
CP47-497 C6H13       
CP47-497-C8 C7H15       
G 
JWH-018 C5H11       
JWH-073 C4H9       
JWH-1503 C5H10F       
JWH-200 (CH2)2N(CH2)4O       
H 
mCPP Cl H      
TFMPP H CF3      
Figure 1 Chemical structures of the 51 substances target analyzed by LC-ESI-MS/MS developed method. 
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Blank samples 
 
Drug free pools whole blood samples were obtained from two 
volunteers by the laboratory itself (n=1) and from fifty-five 
post mortem individuals (n=5), unidentified and all preserved 
with sodium fluoride and EDTA. 
The same pools of negative samples have undergone 
modifications to simulate how the biological samples are 
eventually sent to the laboratory, which were: three heating 
cycles (40°C for 12 h) or dilution (20% in ultrapure water) or 
addition of nitrite (0.5 mg L-1). 
 
Blood extraction 
 
The developed method was based on the work published by 
Marinetti and Antonides (8). Nordizepam-d5 internal 
standard solution (4 µL), sodium hydroxide solution (200 µL) 
and extraction mixture solvent (500 µL) were added to 500 
µL whole blood sample, which was homogenized for 7 
minutes at medium speed. After centrifugation at 10000 rpm 
for 7 min, the supernatant was transferred into vial. The 
aqueous residue was re-extracted with a second aliquot of 500 
µL of extracting mixture solvent and the organic extracts 
were gathered in the same vial. After evaporation to dryness 
(at room temperature or up to 45 degrees), the residue was 
transferred to an insert with two aliquots of 25 μL each of 
mobile phase mixture A and B (1:1) and 18 µL were injected 
onto the LC-ESI-MS/MS for analysis. 
 
Method Validation 
 
The analytical method was validated in accordance with 
recommendations for qualitative analysis in biological 
specimens of UNODC (9), whose parameters were 
specificity, limits of detection, and precision under 
repeatability and reproducibility condition. The evaluation of 
the matrix effect was performed according to Brazilian 
Sanitary Surveillance Agency (10). 
 
Specificity 
 
Drug free pooled (n=6) whole blood samples were analyzed 
to verify the absence of interfering endogenous substances at 
the retention times of the analytes target and of the internal 
standard. Additionally, a blank whole blood sample from a 
living individual containing substances (n=39) that could be 
present in the forensic biological samples, in more than one 
concentration, recreational or therapeutic (11,12), were 
analyzed (Table 1). The specificity of the method was also 
evaluated after heating cycles, dilution and in the presence of 
sodium nitrite. 
 
Limits of detection 
 
Detection limits were obtained by extracting whole blood 
samples containing analytical standards from their respective 
therapeutic (or recreational) concentrations, increasing 
concentration or decreasing, until the results met the criteria 
of acceptability, which were: presence of all transitions at the 
same retention time, proportion of transitions within 
acceptable tolerance (13) and minimum abundance (3 x 102), 
whose definition occurred from blank assays. 
 
Precision 
 
Original drug free pooled matrix (n=6) and modified (n=3) 
containing substances target at their detection limits were 
analyzed on four days in duplicate. The repeatability of 
retentions time was evaluated through the coefficient of 
variation (CV%) values. 
 
Matrix effect 
 
Drug free pools matrices (n=6) were extracted and, 
posteriorly, added at concentrations in the respective 
detection limits. Ion suppression or enhancement was 
calculated by matrix factor normalized by PI (FMN), 
according to the Equation 1, below, evaluating the CV% 
values among matrices analyzed. 
 
𝐹𝑀𝑁 =
peak area of drug in matrix peak area of PI in matrix⁄
peak area of drug in mobile phase peak area of PI in mobile phase⁄
 
Eq. 1 
 
Stability 
 
Standard solutions, including internal standard, were 
prepared and used for method development and validation 
within a time period ranging from 16 to 20 months, always 
keeping refrigerated (4°C). The sample extracts were 
resuspended in mobile phase only on the day of injection in 
the equipment, remaining in the refrigerated sampler for a 
maximum of 24 h before analysis. 
 
Results and Discussion 
 
The necessary reference standards for the development and 
validation of forensic routine methods of emerging NPS are 
available from industrial sources, but only after a 
considerable time delay and at significant cost. To address 
this issue, the use of confiscated samples, after chemical 
purification processes, as a reference may solve the problem 
(2). This strategy has been adopted by DPL-IGP/RS in recent 
years. 
Figure 2 shows the chromatogram obtained after the analysis 
of a whole blood sample containing the 51 substances target. 
Even though some analytes had very similar or equal 
retention times, there was no influence on the detection of 
each one, allowing the simultaneous analysis of all substances 
of interest.  
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Figure 2 Chromatogram obtained by LC-ESI-MS/MS in whole blood containing the 51 substances target at the respective detection limits after 
extraction of the monitored transitions overlap. 
 
Specificity 
 
The tests with modified matrices aimed to verify if, an 
eventual, lack of refrigeration of the samples, collection of 
sites containing mixing of blood with other body fluids or the 
presence of sodium nitrite could harm the method developed 
by produce any unwanted interferences. In the state of RS 
there is only one forensic laboratory, located in Porto Alegre, 
where all the biological specimens from the interior are 
transported and some temperature problems may occur 
during this transport. Furthermore, depending on the state of 
putrefaction of the body, blood samples may be collected 
with other body fluids, diluting matrix components. 
Moreover, the developed method will also be used to analyse 
 
 samples of suicide victims, which may be under the influence 
of psychotropic substances at the time of death. A common 
form of suicide in RS is the intake of sodium nitrite (salitre). 
This salt is used in the food industry to preserve the color of 
canned meat and sausages, as well as to prevent the spread of 
botulism-causing bacteria (14), but in a concentration higher 
than 0.5 mg L-1 can cause death (11). The evaluation of the 
specificity of the method in the presence of sodium nitrite 
occurred because the interface used in the equipment was ESI 
type, which may suffer interference due to salts in the sample. 
No original or modified matrix and no other illicit substance, 
drug, metabolite or adulterant interfered with retention time 
of analytes target or of internal standard (Figure 3), no false 
positive result was observed. 
 
 
Figure 3 Chromatogram obtained by LC-ESI-MS/MS after extraction of the monitored transitions overlap in whole blood containing the 
substances listed in Table 1, at their highest concentrations, for evaluation of the specificity of the method
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Limits of detection 
 
To detect the use of NPS, metabolites and/or the parent 
molecule, is a particular analytical challenge in biofluids, 
being difficult because of the low concentrations encountered 
for the more potent substances and the lack of knowledge 
about many of them (15-20). Table 2 shows the analytical 
conditions defined for each substance with the respective 
detection limits obtained. For most of the analytes, 
fortunately, the values found were in the recreational or 
therapeutic range, making it possible to assess whether the 
victims were under the effect of the substances at the time of 
death. 
 
Precision 
 
Retention times presented CV% values ranging from 0.29 to 
1.44, demonstrating a precision adequate, less than 2%. No 
false negative results were observed between the original and 
modified matrices. 
 
Matrix effect 
 
The potential impact of post mortem matrix-related effects on 
standard analytical methods and the interpretation of results 
are examples of issues relating to forensic toxicology (2), that 
is why, although the guide used as a reference for the 
validation of the qualitative method did not suggest the 
evaluation of the matrix effect, this parameter has been 
evaluated. Besides that, according to several authors (21-23), 
LC method coupled to the ESI ionization source suffers more 
influence of the matrix components. 
Table 3 shows the FMN obtained for the substances that 
presented CV% around 15, considered satisfactory. These 
results indicate that, for these substances, there is a potential 
use of the method developed for quantitative analysis after 
the evaluation of the other validation parameters, however 
considering that FMN values lower than 1 had the signal 
suppressed in the matrix presence and those with values 
greater than 1, increment. 
 
Table 3 FMN values obtained during matrix effect evaluation [10] with drug free pools whole blood samples by LC-ESI-MS/MS. 
Substance 
Alive Post mortem 
Mean CV% 
Pool 1 Pool 2 Pool 3 Pool 4 Pool 5 Pool 6 
25B-NBOH 0.9 0.9 0.8 0.9 0.9 0.8 0.9 4.8 
25C-NBOH 0.9 0.7 0.8 0.9 0.9 0.8 0.9 9.7 
25E-NBOH 0.8 0.9 0.9 0.9 0.9 0.8 0.9 5.1 
25I-NBOH 1.0 0.9 0.8 0.9 0.9 0.8 0.9 6.2 
5-MeO-MIPT 1.0 0.8 0.9 1.0 0.9 0.7 0.9 12.9 
ADB-Fubinaca 0.6 0.5 0.5 0.5 0.6 0.4 0.5 14.8 
Alfentanyl 1.4 1.3 1.3 1.3 1.3 1.3 1.3 3.3 
Clobenzorex 1.2 0.8 1.0 1.0 1.0 0.7* 1.0 11.5 
CP-047-497 0.7 0.7 0.6 0.7 0.8 0.4* 0.7 12.9 
CP-047-497-C8 0.6 0.6 0.4 0.6 0.6 0.3* 0.6 15.8 
DOB 1.1 1.2 1.0 1.2 1.1 1.0 1.1 8.6 
DOC 0.9 1.0 0.9 0.8 0.8 0.2* 0.9 8.6 
DOI 1.0 1.0 1.3 1.1 1.2 1.0 1.1 9.5 
Fenproporex 1.0 1.0 1.0 0.7 1.0 0.3* 0.9 15.9 
Fentanyl 1.3 1.3 1.3 1.2 1.3 1.4 1.3 6.1 
HU-210 0.6 0.6 0.4 0.6 0.6 0.4* 0.6 14.4 
JWH-018 0.3 0.3 0.3 0.3 0.3 0.2* 0.3 12.5 
JWH-073 0.7 0.7 0.5 0.6 0.7 0.4* 0.6 9.1 
JWH-1503 0.6 0.5 0.4 0.5 0.5 0.4 0.5 14.6 
JWH-200 0.8 1.0 0.8 1.0 1.0 0.8 0.9 13.2 
JWH-250 0.7 0.7 0.6 0.7 0.7 0.5 0.7 14.8 
MBDB 1.3 1.5 1.1 1.6 1.4 2.9* 1.3 13.7 
MDEA 1.0 1.0 0.8 0.9 1.0 0.8 0.9 10.2 
Methylphenidate 1.9 2.7 2.3 2.4 2.6 3.2* 2.4 13.5 
*value discarded 
 
It is important to note, however, that there are often no 
defined concentration ranges associated with NPS that would 
correspond to degrees of toxicity and expected outcomes that 
indicates the likely role of a substance in contributing to or 
causing death (24).  
On the other hand, the substances not listed in Table 3 showed 
great variability in the FMN factors obtained, demonstrating 
the application of the method developed for their qualitative 
analysis only, since all met the criteria for positivity. 
For the epidemiological surveillance of NPS, the challenge is 
that at least qualitative results (detection and identification) 
are reported owing to the specific problems associated with 
the large and rapidly growing number of NPS. Indeed, there 
are special requirements in post mortem analysis and 
difficulties in their interpretation, which challenge forensic 
laboratories (2). 
Post mortem blood samples are often hemolyzed and mixed 
with other biological fluids and tissues in decomposition, 
depending on the time between death and necropsy. The 
presence of large amounts of lipids in these samples is 
common and their interference in the analytical method was 
evaluated together with the other parameters. 
 
Stability 
 
Throughout the development of the method and validation, it 
was observed that the analyte areas varied slightly but 
remained sufficiently intense to meet all positivity criteria. 
One of the major limitations in forensic toxicology is the 
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difficulty in obtaining reference standards as well as the small 
quantity of them, when available. Thus, stability is considered 
adequate as long as unambiguous identification of the 
substance is possible, even if there is some degradation. 
 
Conclusion 
 
The proposed LC-ESI-MS/MS method can be regarded as 
selective and validated for qualitative forensic analysis. 
Among the advantages of this method we have the ease of 
execution without the need for expensive consumables and a 
25 min analytical run detecting 51 analytes simultaneously 
through a method accessible for medium laboratories of 
toxicology in countries such as Brazil, where the abuse of 
NPS compounds are increasing exponentially, and are 
considered as a public health problem. 
 
Acknowledgments 
 
The authors thank the Dra. Bianca de Almeida Carvalho and 
Daniel Scolmeister (IGP-RS) for their assistance, support and 
conditions for the execution of this work and to the National 
Council for Scientific and Technological Development 
(CNPq). 
 
Interest conflicts 
 
The authors declare no conflicts of interest. 
 
References 
 
1. United Nations Office on Drugs and Crime (UNODC). 
World Drug Report 2019. Vienna, Austria, 2019. 90p. 
 
2. European Monitoring Centre for Drugs and Drug 
Addiction. Technical Report. An analysis of post mortem 
toxicology practices in drug-related death cases in 
Europe, 2019. 
 
3. Franck MC, Meneghini LZ, Rossato LG, Limberger RP, 
Froehlich PE. Development and validation of an LC-UV 
method for quantitation of 4-bromo-
2,5dimethoxyamphetamine (DOB), 4-bromo-
2,5dimethoxyphenetylamine (2C-B), methylphenidate, 
fenproporex and amfepramone. Chromatographia 
Supplement. 2009; 69: S143-8. 
 
4. Correa PS, Gris LRS, Wegner PB, Bettoni CC, Baggio 
EV, Carpes MJS. Caracterização de designer drugs 
apreendidas no estado do Rio Grande do Sul. In: Inter 
Forensics - Conferência Internacional de Ciências 
Forenses, May 23-25, 2017, Brasília, Brazil. 
 
5. Nunes CC, Scolmeister D, Wegner PB, Silva SM, Bettoni 
CC, Gris LRS, et al. Results obtained in the analysis of 
materials submitted to ecstasy research in RS in years 
2012 and 2013. In: ToxiLatin 1º Congresso latino-
americano de toxicologia clínico-laboratorial, April 27-
30, 2014, Porto Alegre, Brazil. 
 
6. Nunes CC, Wegner PB, Gris LRS, Correa PS. Synthetic 
drugs profile in Rio Grande do Sul in 2015 and its 
implications in use by vehicle drivers. In: 21 st 
International council on alcohol, drugs and traffic safety 
conference, October 16-19, 2016, Gramado, Brazil. 
 
7. Scientific Working Group for the Analysis of Seized 
Drugs (SWGDRUG). Recommendations version 8. USA, 
2019. 83p. 
 
8. Marinetti LJ, Antonides HM. Analysis of synthetic 
cathinones commonly found in bath salts in human 
performance and post mortem toxicology: method 
development, drug distribution and interpretation of 
results. J Anal Toxicol, 2013;37:135-146. 
 
9. United Nations Office on Drugs and Crime (UNODC). 
Guidance for the validation of analytical methodology 
and calibration of equipment used for testing of illicit 
drugs in seized materials and biological specimens. 
Vienna, Austria, 2009. 76p. 
 
10. Brazil. Agência Nacional de Vigilância Sanitária. RDC n° 
27 de 17 de maio de 2012. Requisitos mínimos para 
validação de métodos bioanalíticos, Diário Oficial da 
União: Brasília. 
 
11. Moffat AC, Osselton MD, Widdop B, Watts J. Clarke´s 
analysis of drugs and poisons in pharmaceuticals, body 
fluids and post mortem material. 4 th ed. Pharmaceutical 
Press: London; 2011. 
 
12. Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt 
A. Therapeutic and toxic blood concentrations of nearly 
1,000 drugs and other xenobiotics. Critical Care, 
2012;16:R136. 
 
13. European Commission. Directive 96/23/EC concerning 
the performance of analytical methods and the 
interpretation of results. Official Journal, 2002;L221:8-
36. 
 
14. Iamarino LZ, Oliveira MC, Antunes MM, Oliveira M, 
Rodrigues RO, Zanin CICB, et al. Nitritos e nitratos em 
produtos cárneos enlatados e/ou embutidos. Gestão em 
Foco, 2015;7:246-251. 
 
15. Kyriakou C, Marinelli E, Frati P, Santurro A, Afxentiou 
M, Zaami S, et al. NBOMe: new potent hallucinogens – 
pharmacology, analytical methods, toxicities, fatalities: a 
review. Eur Rev Med Pharmacol Sci, 2015;19:3270-3281. 
 
16. Suzuki J, Dekker MA, Valenti ES, Arbelo FAC, Correa 
AM, Poklis JL, et al. Toxicities associated with NBOMe 
ingestion, a novel class of potent hallucinogens: a review 
of the literature. Psychosomatics, 2015;56(2):129-139. 
 
17. Wood DM, Sedefov R, Cunningham A, Dargan PI. 
Prevalence of use and acute toxicity associated with the 
use of NBOMe drugs. Clin Toxicol, 2015;(53)85. 
 
18. Kerrigan S, Mott A, Jatzlau B, Ortiz F, Perrella L, Martin 
S, et al. Designer psychostimulants in urine by liquid 
 
       Drug Anal Res, 2019; v. 3, n. 02, 36-45 
45 
 
chromatography-tandem mass spectrometry. J. Forensic 
Sci, 2014;59(1):175-183. 
 
19. Fagiola M, Hahn T, Avella J. Screening of novel 
psychoactive substances in post mortem matrices by 
liquid chromatography-tandem mass spectrometry (LC-
MS-MS). J Anal Toxicol, 2018;42(8):562-569. 
 
20. Ong RS, Kappatos DC, Russell SGG, Poulsen HA, 
Banister SD, Gerona RR, et al. Simultaneous analysis of 
29 synthetic cannabinoids and metabolites, amphetamines 
and cannabinoids in human whole blood by LC-MS/MS - 
A New Zealand perspective of use in 2018. Drug Test 
Anal., 2019. doi: 10.1002/dta.2697. 
 
21. Fang N, Yu S, Ronis MJ, Badger TM. Matrix effects 
break the LC behavior rule for analytes in LC-MS/MS 
analysis of biological samples. Exp Biol Med, 
2015;240:488-497. 
 
22. Matuszewski BK, Constanzer ML, Chavez-Eng CM. 
Strategies for the assessment of matrix effect in 
quantitative bioanalytical methods based on HPLC-
MS/MS. Anal. Chem., 2003;75(13):3019-3030. 
 
23. Rudzki PJ, Gniazdowska E, Buś-Kwaśnik K. Quantitative 
evaluation of the matrix effect in bioanalytical methods 
based on LC-MS: a comparison of two approaches. J 
Pharmaceut Biomed, 2018. DOI: 
10.1016/j.pba.2018.03.052. 
 
24. Elliott S, Sedefov R, Evans-Brown M. Assessing the 
toxicological significance of new psychoactive 
substances in fatalities. Drug Test Anal., 2017;10:120-
126. 
 
